Guggenheim Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

Key Points

• Guggenheim raised its Revolution Medicines price target to $275 from $240 and maintained a “Buy” rating, implying about 24% upside from the reported $221.15 share price.
• Analyst sentiment is broadly bullish: TD Cowen upgraded the stock to “Strong Buy,” while several firms raised targets between $251 and $320. MarketBeat’s consensus is “Moderate Buy,” with a $195.22 average target.
• Shares have surged near their 52-week high, but the company reported a larger-than-expected quarterly loss of $3.06 per share versus a $2.04 consensus estimate. Investors are also weighing the commercial potential of FDA-approved RASONQUE against launch, reimbursement and pricing risks.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) had its target price raised by equities researchers at Guggenheim from $240.00 to $275.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's target price points to a potential upside of 24.35% from the stock's current price.

A number of other research firms also recently weighed in on RVMD. TD Cowen raised Revolution Medicines to a "strong-buy" rating in a report on Monday. Oppenheimer increased their target price on Revolution Medicines from $230.00 to $260.00 and gave the stock an "outperform" rating in a report on Thursday. Evercore reaffirmed an "outperform" rating and issued a $320.00 price target on shares of Revolution Medicines in a research note on Thursday. HC Wainwright upped their price target on Revolution Medicines from $195.00 to $280.00 and gave the company a "buy" rating in a research report on Thursday. Finally, Royal Bank Of Canada increased their price objective on Revolution Medicines from $203.00 to $251.00 and gave the stock an "outperform" rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Revolution Medicines has a consensus rating of "Moderate Buy" and a consensus price target of $195.22.

Revolution Medicines Trading Up 2.7%

Shares of RVMD stock opened at $221.15 on Friday. The firm has a fifty day moving average of $192.43 and a 200-day moving average of $148.17. The stock has a market cap of $47.40 billion, a price-to-earnings ratio of -25.07 and a beta of 1.39. Revolution Medicines has a 52-week low of $37.56 and a 52-week high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter last year, the business posted ($1.31) EPS. On average, equities research analysts forecast that Revolution Medicines will post -8.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Margaret A. Horn sold 60,400 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the sale, the chief operating officer directly owned 158,222 shares in the company, valued at $25,342,417.74. This represents a 27.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark A. Goldsmith sold 80,000 shares of Revolution Medicines stock in a transaction on Friday, August 21st. The shares were sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the transaction, the insider owned 267,330 shares of the company's stock, valued at approximately $55,925,436. The trade was a 23.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 212,497 shares of company stock worth $38,206,486 over the last ninety days. 7.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RVMD. California State Teachers Retirement System grew its holdings in Revolution Medicines by 26,920.9% during the 2nd quarter. California State Teachers Retirement System now owns 44,659,351 shares of the company's stock worth $8,363,803,000 after acquiring an additional 44,494,074 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Revolution Medicines by 6.7% in the fourth quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company's stock worth $1,331,739,000 after acquiring an additional 1,056,792 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Revolution Medicines by 8.3% during the fourth quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company's stock worth $980,036,000 after purchasing an additional 947,448 shares in the last quarter. Nextech Invest Ltd. grew its stake in shares of Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP grew its stake in shares of Revolution Medicines by 6.8% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 6,644,403 shares of the company's stock valued at $529,227,000 after purchasing an additional 421,112 shares during the last quarter. 94.34% of the stock is owned by institutional investors.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial catalyst. RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, potentially establishing a new treatment option for patients with limited alternatives. FDA approval announcement
• Positive Sentiment: Analysts remain bullish after the approval. HC Wainwright reiterated a “Buy” rating and a $280 price target, above the referenced $221.15 price, while forecasting a narrower FY2027 loss of $6.86 per share. Truist also raised its target to $239 and Wedbush increased its target to $225, both maintaining positive ratings.
• Positive Sentiment: Early launch expectations are favorable. RBC reportedly views the RASONQUE launch as capable of moving quickly, while Oppenheimer said the product’s label expands Revolution Medicines’ commercial opportunity. The company’s decision to remain independent could allow shareholders to retain greater value from the drug’s potential.
• Neutral Sentiment: Near-term financial results will still reflect a development-stage business. HC Wainwright projects quarterly 2027 losses of $2.06, $1.70, $1.62 and $1.47 per share, for a full-year loss of $6.86 per share. Investors are likely to focus on prescription trends, reimbursement and initial revenue after the launch.
• Negative Sentiment: RASONQUE’s $39,800 monthly price may create access and reimbursement risks. Although the price supports substantial revenue potential, it could attract scrutiny from payers and policymakers or slow patient access, tempering some of the enthusiasm surrounding the FDA decision. RASONQUE pricing article

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source